Mutations in the Schmallenberg Virus Gc Glycoprotein Facilitate Cellular Protein Synthesis Shutoff and Restore Pathogenicity of NSs Deletion Mutants in Mice

Mariana Varela, Rute Maria Pinto, Marco Caporale, Ilaria M. Piras, Aislynn Taggart, Frauke Seehusen, Kerstin Hahn, Anna Janowicz, William Marciel de Souza, Wolfgang Baumgärtner, Xiaohong Shi, Massimo Palmarini

MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland; Istituto Zooprofilattico Sperimentale dell’Abruzzo e Molise G. Caporale, Teramo, Italy; Department of Pathology and Center of Systems Neuroscience, University of Veterinary Medicine, Hannover, Germany; Virology Research Center, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil

ABSTRACT
Serial passage of viruses in cell culture has been traditionally used to attenuate virulence and identify determinants of viral pathogenesis. In a previous study, we found that a strain of Schmallenberg virus (SBV) serially passaged in tissue culture (termed SBVp32) unexpectedly displayed increased pathogenicity in suckling mice compared to wild-type SBV. In this study, we mapped the determinants of SBVp32 virulence to the viral genome M segment. SBVp32 virulence is associated with the capacity of this virus to reach high titers in the brains of experimentally infected suckling mice. We also found that the Gc glycoprotein, encoded by the M segment of SBVp32, facilitates host cell protein shutoff in vitro. Interestingly, while the M segment of SBVp32 is a virulence factor, we found that the S segment of the same virus confers by itself an attenuated phenotype to wild-type SBV, as it has lost the ability to block the innate immune system of the host. Single mutations present in the Gc glycoprotein of SBVp32 are sufficient to compensate for both the attenuated phenotype of the SBVp32 S segment and the attenuated phenotype of NSs deletion mutants. Our data also indicate that the SBVp32 M segment does not act as an interferon (IFN) antagonist. Therefore, SBV mutants can retain pathogenicity even when they are unable to fully control the production of IFN by infected cells. Overall, this study suggests that the viral glycoprotein of orthobunyaviruses can compensate, at least in part, for the function of NSs. In addition, we also provide evidence that the induction of total cellular protein shutoff by SBV is determined by multiple viral proteins, while the ability to control the production of IFN maps to the NSs protein.

IMPORTANT
The identification of viral determinants of pathogenesis is key to the development of prophylactic and intervention measures. In this study, we found that the bunyavirus Gc glycoprotein is a virulence factor. Importantly, we show that mutations in the Gc glycoprotein can restore the pathogenicity of attenuated mutants resulting from deletions or mutations in the nonstructural protein NSs. Our findings highlight the fact that careful consideration should be taken when designing live attenuated vaccines based on deletions of nonstructural proteins since single mutations in the viral glycoproteins appear to revert attenuated mutants to virulent phenotypes.

The family Bunyaviridae is one of the largest families of RNA viruses, comprising pathogens of importance for both human and veterinary medicine. More than 170 viruses transmitted by arthropods form the Orthobunyavirus genus. Schmallenberg virus (SBV) is an orthobunyavirus of ruminants that emerged in central Europe in the summer of 2011 and spread very quickly throughout the rest of the continent (1). Although SBV genomes and antibodies have been detected in wild ruminants, camels, and a dog, so far only infections of ruminants have been associated with the disease (2–4). SBV has been detected in various Culicoides species, and it is assumed that these insects provide the main route of transmission for this virus (5, 6).

Infection of adult animals with SBV results in unspecific and mild clinical signs, while infection during gestation can result in stillbirths, abortions, and malformations similarly to infections with related viruses of the Simbu serogroup, like Akabane virus (AKAV), Sathuperi virus (SATV), and Shamonda virus (SHAV) (7, 8). SBV was not detected in archived brain samples, and no evidence of antibodies toward this virus was found in sera collected before 2010 in ruminants (9, 10). Hence, it is believed that the virus emerged for the first time in Europe in 2011. However, there is little information on the viral genetic characteristics and ecological conditions driving SBV emergence.

Like other orthobunyaviruses, the SBV genome comprises...
three RNA segments of negative polarity, referred to as small (S), medium (M), and large (L). The S segment encodes the viral nucleocapsid and the nonstructural protein NSs in an overlapping reading frame. The M segment encodes the viral glycoproteins Gn and Gc, decorating the viral lipid bilayers, in addition to the NSm glycoprotein, a second nonstructural protein with poorly defined characteristics. The L segment encodes the viral RNA-dependent RNA polymerase (RdRp).

Using reverse genetics, we and others have previously shown that the SBV NSs protein is a determinant of pathogenesis (11–13). Deletion of the SBV NSs protein results in attenuation of pathogenicity in a suckling mouse model of infection. In vitro, NSs deletion (SBV-ΔNSs) leads to (i) impaired virus replication in interferon (IFN)-competent cells, (ii) an inability to inhibit IFN synthesis in infected cells, and (iii) an inability to induce cellular protein synthesis shutoff. The defects possessed by SBV-ΔNSs are the result, at least in part, of the incapacity of the mutated virus to induce the degradation/dephosphorylation of the cellular RNA polymerase II as a means of inhibiting cellular transcription and the IFN response of the host (12). Regulatory authorities in some European countries have granted provisional marketing authorization for an inactivated SBV vaccine (14). In addition, an NSs-NSm double-deletion SBV mutant has been proposed as a vaccine candidate, as it provides full protection in cattle upon wild-type virus challenge and does not induce viremia or clinical signs in cattle (15).

In an attempt to identify other viral determinants of pathogenicity, we serially passaged SBV in sheep IFN-incompetent cell lines. Our results indicated that the SBVp32 strain, derived in this study, was passaged 32 times in cell culture. SBV-SML32 contains all the segments from SBVp32 but was derived by reverse genetics. A deletion mutant of the NSm protein was constructed by mutagenesis of the SBV M segment by deletion of amino acid residues 338 to 448 (X. Shi and R. M. Elliott, unpublished results).

**Labeling of nascent proteins with puromycin.** Monolayers of CPT-Tert cells at 30 to 40% confluence were infected with the indicated viruses at a multiplicity of infection (MOI) of 1. At 16 h postinfection, the medium was replaced with IMDM supplemented with 10 μg/ml puromycin dihydrochloride (Sigma) for 12 min. Cells were then washed with phosphate-buffered saline (PBS) and lysed by using 1× Laemmli buffer. SDS-PAGE and Western blotting were performed by using total cell lysates as previously described (18). For quantitative Western blotting, primary antibodies were detected by using peroxidase-labeled secondary antibodies with a ChemiDoc XR+ scanner and quantified with Image Lab software (Bio-Rad). γ-Tubulin was used to normalize loading. All experiments were performed independently at least three times. For each virus, at least two independent virus preparations were used.

**Virus replication assays.** Virus replication kinetics were determined by infection of the indicated cell lines at an MOI of 0.001, unless stated otherwise, followed by titration of supernatants collected at different time points postinfection by limiting-dilution assays in BSR-T7/5 cells. Titters are expressed as the 50% tissue culture infectious dose (TCID₅₀) (determined by the Reed-Muench method [31]). Each experiment was performed in triplicate and repeated three times using two different virus preparations.

**Immunofluorescence and confocal microscopy.** The indicated cell lines were infected with the indicated viruses and fixed with 5% formaldehyde, followed by immunofluorescence using a polyclonal antiserum toward the SBV N protein, as previously described (19, 20). Slides were analyzed by using a Leica DMIR2 confocal microscope.

**IFN bioassays.** Primary sheep fibroblasts were infected with the indicated reassortants (MOI of 1 or 0.5), and at 16 h postinfection, the supernatants were collected and clarified. UV-inactivated supernatants were used to stimulate A549-IRF-3-GFP cells for 24 h when cells were fixed, and the number of GFP positive cells was determined by fluorescence-activated cell sorter (FACS) analysis. The amount of IFN present in each sample was estimated based on an IFN standard of a known concentration.

**Quantification of viral mRNA.** Viral RNA was reverse transcribed by using an SBV-specific primer (5′-TTCGCGCCCAAGGTGCAAATC-3′) with AccuScript HF reverse transcriptase according to the manufacturer’s instructions, using 200 μg of total RNA. Two microliters of cDNA was used for quantitative reverse transcription-PCR (qPCR) (qRT-PCR) using Brilliant III Ultra Fast QPCR master mix as suggested by the manufacturer. The primers and probe used are as follows: SBV-S-FW (TCA GATTGTGATGGGCCCTTGC), SBV-S-RW (TTCGGCCCAAGGTGCAAATC), and SBV-S-FAM (TTAAGGGATGCACCTGGGCCGATGGC). Reactions were analyzed on a Stratagene MX3000 qPCR system (Agilent Technologies), and data were analyzed with Mx3000P software.
**Histopathology and in situ hybridization.** Organ samples were fixed in formalin and embedded in paraffin using standard histological techniques. Slides were stained with hematoxylin and eosin (H&E).

*In situ* hybridization (ISH) to detect SBV mRNA was performed on all sections as described previously (21). Briefly, paraffin sections were dehydrated, hydrated, and washed in diethyl pyrocarbonate (DEPC)-treated water. After proteolytic digestion, postfixation, acetylation, and prehybridization, sections were hybridized overnight with a digoxigenin (DIG)-labeled probe (88 bp; 100 ng/ml) directed against the SBV nucleoprotein (21). Hybridized probes were detected by using an anti-DIG antibody conjugated with alkaline phosphatase and the substrates nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (X-phosphate). SBV-positive and -negative animals as well as sections incubated with only hybridization buffer were included as controls.

**In vivo experiments.** Animal experiments were carried out at the Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Caporale (Teramo, Italy) in accordance with locally and nationally approved protocols regulating animal experimental use (protocol number 5383/2012). For survival studies, suckling NIH-Swiss mice (n = 10 to 15 per group) were inoculated intracerebrally with 400 PFU of the indicated reassortants/mutants and monitored daily for signs of disease for a period of 14 days. In order to test virus spread in the brain, 5-day-old NIH-Swiss mice (n = 3 per virus and time point) were inoculated intracranially with SBV, SBV-SML32, and SBV-M32 and euthanized at 8, 24, 48, and 72 h postinfection. Pathogenicities of SBV and SBVp32 were also compared in adult IFNAR−/− mice, where groups of 5 mice were inoculated intraperitoneally (1,000 PFU) and weight was recorded over a 15-day period. For histology and ISH, IFNAR−/− mice (n = 2 per virus) were inoculated with either SBV, SBVp32, or uninfected cell culture medium, and animals were euthanized at 3 days postinfection. Organs were then collected for histological examination and ISH.

**Statistical analysis.** Statistical analysis was performed by using GraphPad Prism. All graphs display data averages and standard deviations.

**RESULTS**

The M segment is a major determinant of SBVp32 virulence. Our first goal was to identify the viral genomic segment(s) conferring higher virulence to SBVp32. To this end, we rescued SBV, SBVp32, and the reassortants between the two viruses mentioned below by reverse genetics as previously described (Fig. 1A) (11). Table 1 shows the mutations present in the viruses used in this study.

We inoculated 11-day-old NIH-Swiss mice intracerebrally (400 PFU) with all the reassortants, and survival was monitored for 15 days. All the reassortants carrying the M segment of SBVp32 were more pathogenic than wild-type SBV (P ≤ 0.01 for SBV-SML32 and P ≤ 0.0001 for SBV-M32, SBV-SM32, and SBM-SL32). These data suggest that the pathogenicity of SBVp32 maps to the M segment. A reassortant carrying the L segment of SBVp32 (SBV-L32) displayed the same pathogenicity as that of wild-type SBV; however, somewhat surprisingly, a reassortant carrying the S segment of SBVp32 (SBV-S32) was attenuated (Fig. 1B). It is interesting to note that the attenuation conferred by the S segment of SBVp32 maps to the M segment. A reassortant carrying the L segment of SBVp32 (SBV-L32) displayed the same pathogenicity as that of wild-type SBV; however, somewhat surprisingly, a reassortant carrying the S segment of SBVp32 (SBV-S32) was attenuated (Fig. 1B). It is interesting to note that the attenuation conferred by the S segment of SBVp32 could be compensated for by the M segment of SBVp32, since the SBV-SM32 mutant was more pathogenic than the wild type (P ≤ 0.0001).

We previously showed that SBVp32 spreads faster in the brains of infected mice (11). To understand the possible mechanisms behind the extra pathogenicity conferred by the M segment of SBVp32, we compared the amounts of virus found in brains of 6-day-old NIH-Swiss mice infected intracranially with wild-type SBV, SBV-SML32, and SBV-M32. For each virus, groups of 3 mice were killed at different times postinfection (8, 24, 48, and 72 h), and total RNA was extracted from brains, followed by qRT-PCR to quantify the number of SBV genome equivalents. We found that both SBV-SML32 and

---

**FIG 1** SBVp32 pathogenicity maps to the M segment. (A) Schematic representation of SBV reassortants generated by reverse genetics. (B) Survival plots of 11-day-old NIH-Swiss mice inoculated intracerebrally with 400 PFU of the indicated reassortants. Percent survival of mice inoculated with wild-type SBV is included in each panel to facilitate comparisons. Asterisks indicate significance levels (**, P ≤ 0.01; ****, P ≤ 0.0001 [as determined by a log rank test and a Mantel-Cox test]). d.p.i., days postinfection.
SBV-M32 reached higher numbers of viral genomes than those of wild-type SBV in the brains of infected mice (Fig. 2).

**SBV-S32 attenuation maps to a single nucleotide change within the S segment.** We first investigated the molecular determinants of the SBV-S32 attenuated phenotype. We derived 4 single mutant viruses (SBV-S-C66T, SBV-S-G124A, SBV-S-A167G, and SBV-S-A319G) where the nucleotide at position 66, 124, 167, or 319 of the SBV S segment was mutated to the corresponding nucleotide found in SBVp32, while the M and L segments were identical to those of wild-type SBV. These mutants were used to inoculate suckling mice. All the mutants killed 100% of mice similarly to wild-type SBV except for mutant SBV-S-A167G (carrying a G-to-A mutation corresponding to nucleotide 167 of the viral nucleocapsid gene and nucleotide 142 of the NSs gene), which was markedly attenuated (*P* ≤ 0.05) (Fig. 3A and B).

While all the reassortants had replication kinetics similar to those of wild-type SBV in IFN-incompetent cells (CPT-Tert cells), replication of the SBV-S-A167G mutant was impaired in IFN-competent primary sheep fibroblasts (Fig. 3C). These data suggest that the attenuation of the S segment of SBVp32 due to mutation at position 167/142 (N/NSs) is related to the inability of this virus to inhibit the production of IFN. To confirm these data, we tested the ability of each mutant to induce IFN synthesis using an IFN bioassay. Primary sheep fibroblasts were infected with the different mutants, supernatants were collected at 16 h postinfection, and the amount of IFN present was estimated as described in Materials and Methods. As expected, no IFN was produced by cells infected with wild-type SBV, while cells infected with SBV-S32 and SBV-S-A167G induced the release of IFN into supernatants (Fig. 4A).

We have previously shown that the NSs protein of SBV counteracts the antiviral response of the host by inducing the shutoff of host cell protein synthesis, in line with other orthobunyaviruses (11–13, 22). To test if the attenuation of SBV-S32 is related to its inability to block cellular protein synthesis, we labeled nascent proteins with puromycin in cells infected with the mutants described above and compared them by Western blotting. Cells infected with SBV-A167G (carrying a G-to-A mutation corresponding to nucleotide 167 of the viral nucleocapsid gene and nucleotide 142 of the NSs gene), which was markedly attenuated (*P* ≤ 0.05) (Fig. 3A and B).

The M segment of SBVp32 facilitates virus-induced shutoff of host cell protein synthesis. The results obtained so far indicated that SBVp32 is more virulent than wild-type SBV even though it harbors a defective S segment that is unable to counteract the IFN response of the host cell. However, the defect of the S segment can be compensated for, at least in the experimental

### TABLE 1 Nucleotide differences between wild-type SBV and SBVp32

| Segment | SBV nt position | SBV nt | SBVp32 nt | Type of mutation | Location |
|---------|-----------------|--------|-----------|------------------|----------|
| N       | 66              | C      | T         | Synonymous       | N/NSs    |
|         | 124             | G      | A         | Nonsynonymous    | N/NSs    |
|         | 167             | A      | G         | Nonsynonymous    | N/NSs    |
|         | 319             | NA     | A         | Nonsynonymous    | N        |
| M       | 1016            | G      | A         | Nonsynonymous    | NsM      |
|         | 1239            | T      | G         | Nonsynonymous    | NsM      |
|         | 1502            | T      | C         | Nonsynonymous    | Gc “hot spot” |
|         | 1894            | A      | G         | Nonsynonymous    | Gc       |
|         | 2011            | C      | G         | Nonsynonymous    | Gc       |
|         | 2236            | A      | G         | Nonsynonymous    | Gc       |
|         | 2411            | C      | T         | Nonsynonymous    | Gc       |
|         | 2506            | T      | C         | Nonsynonymous    | Gc       |
|         | 2575            | G      | A         | Nonsynonymous    | Gc       |
| L       | 130             | T      | C         | Nonsynonymous    | Endonuclease region |
|         | 3044            | T      | C         | Nonsynonymous    | Gc       |
|         | 3858            | A      | G         | Nonsynonymous    | Gc       |
|         | 4078            | C      | T         | Nonsynonymous    | Gc       |

*nt, nucleotide; NA, not applicable.
mouse model used in our studies, by the M segment of SBVp32. Hence, we tested the ability of reassortants carrying the S segment of SBVp32 in combination with the L and M segments of SBVp32 to shut off protein synthesis by puromycin labeling of nascent proteins. These experiments were designed in order to understand whether the M segment of SBVp32 compensates for the relative inability of the SBVp32 S segment to block cellular protein synthesis. All the controls used in the experiment worked as expected: SBV induced host protein shutoff, while SBV-NSs or SBV-S32 was unable to do so (Fig. 5A). On the other hand, we found that any reassortant carrying the M segment of SBVp32 was able to induce global host protein shutoff, even in the presence of the attenuated S32 segment. In addition, SBV-L32 was also unable to block host protein synthesis, suggesting a role for the polymerase in this process.

We then performed the same assays with reassortants deleted of the NSs protein in combination with the M or L segment of SBVp32 (SBV-ΔNSs-M32 and SBV-ΔNSs-L32). We found that the M segment of SBVp32 was also able to compensate for the defect in host protein shutoff displayed by an NSs deletion mutant (11) (Fig. 5B).

The mutations that accumulated in the M segment of SBVp32 during serial passage map to both the NSm and Gc glycoproteins (Fig. 6A and Table 1). To understand if the increased pathogenicity of SBVp32 maps to the NSm or the Gc glycoprotein, we mutated the NSm nucleotides within the SBV-M32 backbone into those present in wild-type SBV and tested the pathogenicity of the resulting reassortant in our mouse model of infection. We found that a virus carrying a wild-type NSm protein and an SBVp32 Gc protein in combination with L and S segments from wild-type SBV (SBV-Gc32-NSmWT) was more pathogenic than wild-type SBV in suckling mice (P < 0.001) (Fig. 6B). In addition, the same reassortant in the context of an SBV S segment deleted of its NSs protein was still more pathogenic (SBV-S32-Gc32-NSmWT) than wild-type SBV (P < 0.001).

Next, we checked the ability of these mutants to induce total cellular protein shutoff using puromycin labeling of nascent proteins. As expected, we found that all the reassortants carrying the Gc glycoprotein of SBVp32 induced host protein shutoff even in combination with impaired S segments (S32 and ΔNSs) (Fig. 6C). In addition, complete deletion of the NSm protein did not affect the ability of the SBVp32 Gc glycoprotein to shut off total cellular protein production or restore the impaired cellular protein shutoff capability of NSs mutants (SBV-S32-Gc32-ΔNSm and SBV-ΔNSs-Gc32-ΔNSm) (Fig. 6D).

Next, we introduced the individual nonsynonymous nucleotide changes identified in the Gc gene of SBVp32 into SBV by site-directed mutagenesis and rescued each mutant within the
context of a wild-type SBV L segment and the S segment of SBVp32. The resulting mutants were called SBV-S32-MT1502C, SBV-S32-MA1894G, SBV-S32-MC2011G, SBV-S32-MA2236G, SBV-S32-MC2411T, and SBV-S32-MT2506C. Unfortunately, SBV-S32-G2575A could not be successfully rescued despite several attempts. We then assessed the capacity of each mutant to shut off total cellular protein production. We found that mutations at positions 1894, 2236, and 2411 were individually capable of rescuing the defect of the S segment of SBVp32 (Fig. 6E).

The M segment of SBVp32 is not an IFN antagonist. Next, we investigated whether the M segment of SBVp32 could compensate for the inability of the attenuated S32 segment to inhibit the production of IFN. To this end, we first monitored the replication kinetics of various SBVp32–wild-type SBV reassortants in sheep IFN-competent cells. We found that all reassortants carrying the S segment of SBVp32 (including those carrying M32) reached lower titers than those of wild-type SBV (Fig. 7A). These data suggest that the S segment of SBV is by itself the major virus IFN antagonist.

To support these results, we tested the ability of each reassortant to block the synthesis of IFN in infected cells as described above. We found that all the reassortants carrying the S segment of SBVp32 induced the release of IFN from infected cells, even in combination with the M segment of SBVp32, although at lower levels than those for an NSs deletion mutant (Fig. 7B). These data indicate that for SBV, pathogenicity does not totally depend on the...
SBVp32 pathogenicity maps to the Gc glycoprotein. (A) Schematic representation of SBVp32 mutations within the M segment. (B) Survival plots of 8-day-old NIH-Swiss mice inoculated intracerebrally with 400 PFU of the indicated reassortants. Asterisks indicate significance levels (***, $P < 0.001$; ****, $P < 0.0001$ [as determined by a log rank test and a Mantel-Cox test]). (C to E) Western blots displaying puromycin-labeled proteins 16 h after infection with the indicated reassortants (MOI of 1). γ-Tubulin was used as a loading control, and SBV N was used to confirm infection. The numbers indicate the quantification of protein levels in each lane relative to that for mock infection, which was set at 100%.
The capability of the virus to inhibit the production of IFN but rather depends on its ability to induce total cellular protein shutoff. In addition, the data also suggest that virus-induced global protein shutoff is not necessarily sufficient to block the production of IFN in the host.

The glycoprotein of SBVp32 facilitates early events of virus infection. The majority of the amino acid substitutions between wild-type SBV and SBV-M32 map to the Gc glycoprotein. Therefore, we reasoned that during serial passage in tissue culture, the SBV glycoprotein evolved to reach a conformation to allow better entry. To test this hypothesis, we infected CPT-Tert cells with the same number of genome equivalents of SBV, SBV-M32, and SBV-SML32 (all segments from SBVp32), and the number of infected foci was quantified at 8 h postinfection after immune staining. We found a higher number of SBV-positive foci in wells infected with SBVp32 and SBV-M32 than in those infected with wild-type SBV, indicating that the M segment of SBVp32 facilitates early events of SBV infection (Fig. 8).

SBVp32 virulence is also related to increased virus replication in the absence of an intact IFN response. The data obtained so far indicate that SBVp32 virulence is determined by its M segment and in particular by its ability to shut off host protein synthesis and facilitate virus replication. The results obtained using NIH-Swiss mice suggest that SBVp32 virulence is therefore not linked to its ability to block the IFN response of the host. In order to support this conclusion, we compared the pathogenicities of SBV and SBVp32 in adult IFNAR−/− mice. We inoculated three groups of IFNAR−/− mice with SBV, SBVp32, or uninfected cell culture medium as a control (n = 5 per group). All the animals survived for the duration of the experiment, and both SBV- and SBVp32-infected animals developed signs of disease. However, these signs were more pronounced in SBVp32-infected animals. In addition, SBVp32-infected animals displayed statistically significant (P < 0.05) more pronounced weight loss than that in mock-infected controls (Fig. 9A).

Next, we analyzed virus distribution in a variety of organs byISH in three groups of IFNAR−/− mice (n = 2 per group) inoculated with either SBV, SBVp32, or uninfected cell culture medium. Mice were euthanized at 3 days postinfection, and organs were then collected for histological examination and ISH (Fig. 9B). The liver and spleen of SBV-infected animals were the only organs displaying histopathological changes, consisting of mild to moderate inflammation. SBV mRNA was detected by in situ hybridization in both macrophages and hepatocytes in the liver and in macrophages in the spleen. SBV mRNA was also detected in the mandibular and mesenteric lymph nodes. On the other hand, moderate to severe necrosuppurative hepatitis, supplicative splenitis, and lymphadenitis were found in samples derived from SBVp32-infected animals. These lesions were associated with the presence of moderate to large amounts of SBV mRNA in hepatocytes and macrophages. One animal showed nonsuppurative interstitial nephritis that was associated with the presence of mild to moderate amounts SBV mRNA. Degenerative and inflammatory lesions were identified in the heart, while mild pathomorphological changes were present in the small intestine and the spinal cord, but no SBV mRNA was detected in the latter. Table 2 displays the organs in which the presence of SBV mRNA was evaluated.

![FIG 7](http://jvi.asm.org) Replication kinetics of SBVp32 reassortants in IFN-competent cells. (A) Primary sheep fibroblasts were infected (MOI of 0.001) with the indicated reassortants, and samples were collected at the indicated times postinfection. The graph shows the averages of data from four independent experiments. (B) Interferon bioassay. Primary sheep fibroblasts were infected with the indicated reassortants (MOI of 0.5), and the amount of IFN present in supernatants was estimated as described in the legend of Fig. 4.

![FIG 8](http://jvi.asm.org) The SBVp32 glycoprotein is more infectious than the wild-type SBV glycoprotein. CPT-Tert cells were infected with 2.5 × 10^5 genome equivalents of the indicated viruses, and the number of SBV-positive cells was counted at 8 h postinfection after immune staining. Ten view fields were counted under each condition. The percentage of positive cells is presented relative to that of wild-type SBV infection. The experiment was repeated 3 times independently. Data were analyzed by using analysis of variance (P = 0.0076).
The S segment of SBV encodes the nucleocapsid and the non-structural protein NSs in overlapping reading frames. We have previously shown that the SBV NSs protein is a virulence factor that inhibits the synthesis of IFN in infected cells and controls the innate immune system of the host by blocking cellular protein production (11, 12). Thus, it is not surprising that the S segment of SBVp32 lost the ability to repress the production of IFN given that it was serially passaged in CPT-Tert cells (sheep cells that do not produce IFN upon viral infection). The NSs protein of SBVp32 also showed a decreased ability to induce total cellular protein shutoff. These observations suggest that IFN antagonism and the capacity to induce total cellular protein shutoff by the NSs protein are linked and require an arginine residue at position 49. Residue 49 is part of a nucleolar localization signal. Thus, the change from arginine to glycine in SBV p32 is likely associated with a change in the cellular localization of NSs leading to its loss of function and evidenced as an attenuated phenotype in suckling mice. However, pathogenicity is restored and even enhanced in those reassortants that also contain the Gc glycoprotein of SBVp32. The SBVp32 Gc protein acquired the ability to induce total cellular protein shutoff during serial passage but cannot compensate for the IFN antagonism of NSs. Altogether, these data suggest that the capacity to inhibit IFN production by SBV maps mainly to the NSs protein. On the other hand, SBV virulence is associated with the ability of the virus to induce total cellular protein shutoff rather than IFN antagonism. This is further supported by the fact that SBVp32 induces more severe clinical signs in adult IFNAR$^{-/-}$ mice than those induced by wild-type SBV. These data also indicate that the ability to block IFN and induce cellular protein shutoff by the NSs protein comes with a “cost” for the virus that is easily disposed of once it is no longer required.

SBVp32 cannot fully inhibit the synthesis of IFN, and its replication is impaired in IFN-competent cells; however, it is still more pathogenic than wild-type SBV in suckling mice. A possible explanation for these contrasting observations is that in infections with viruses expressing the SBVp32 Gc protein, cellular shutoff precedes the induction of IFN, thus quickly overcoming the up-regulation of IFN-stimulated genes (ISGs) and leading to pathogenicity. We need to take into consideration that we quantified the amount of IFN released into the supernatant of infected cells early in infection (16 h postinfection). It is possible that a different effect on IFN synthesis is seen at later time points during infection, and more studies will be required to address this point. In addition, the IFN bioassays were performed in primary cell cultures derived from adult animals. We have previously shown, as for other viral infections (23, 24), that there is an age-dependent resistance to SBV infection in suckling mice (11) that could be attributed to the development of anatomic barriers, the reticuloendothelial system, and the IFN and immune responses, and thus, the increased pathogenicity of SBVp32 could be due to many factors. It still remains to be determined if SBVp32 is also more pathogenic in ruminants and how this virus controls the innate immune system in its natural host.

Deletion of the NSs protein in wild-type SBV does not lead to a full recovery of protein expression in infected cells (Fig. 4B), indicating that other viral proteins are involved in inducing cellular protein shutoff. In addition, only eight serogroups encode NSs proteins among the viruses of the 15 orthobunyavirus serogroups for which genomic data are available, highlighting the fact that orthobunyaviruses use alternative mechanisms to cope with the
in the innate immune system of the host (25). Here we observed that the L segment of SBV contributes to the induction of cellular protein shutoff given that a reassortant comprising the M and S segments of wild-type SBV and the L segment of SBVp32 (SBV-L32) was less capable of shutting down protein expression than wild-type SBV (Fig. 5A). Although we did not map the particular residues associated with this, we can speculate that a mutation at position 130 could be involved since it sits within the endonuclease motif of the viral polymerase. The endonuclease activity of the bunyavirus polymerase allows a “cap-snatching mechanism” by which the viral polymerase cleaves the 5' cap of cellular mRNAs to use as primers for viral mRNA transcription, thereby reducing the cellular pools of mRNA for translation (26). We also found that the SBV NSm protein contributes to cellular protein shutoff (Fig. 4D). Interestingly, in another study, complete deletion of the NSm coding region resulted in a virus that, within the context of wild-type M and L segments (SBV-ΔNSm), was unable to induce cellular protein shutoff but had no effect on the ability to control the production of IFN in infected cells (R. M. Elliott and X. Shi, personal communication). This is in agreement with results of studies carried out on Bunyamwera virus (BUNV), where deletions of internal domains of NSm resulted in a similar phenotype, although a complete NSm deletion mutant could not be rescued by reverse genetics (27), suggesting that NSm might play different roles in different orthobunyaviruses. Although BUNV NSm has been involved in playing a role in assembly and morphogenesis, its role in controlling the innate immunity of the host requires further investigation.

The molecular mechanism of SBV Gc-induced protein shutoff remains to be determined. However, given that the Gc glycoproteins of other orthobunyaviruses, including SBV, transit from the endoplasmic reticulum (ER) to the Golgi apparatus (28) (not shown), it can be expected that they trigger the ER stress response. Several viruses use this strategy to favor the translation of viral proteins (29). Viral infection can quickly lead to excess protein and the accumulation of misfolded products in the ER, which ultimately results in the phosphorylation of eukaryotic initiation factor 2 (eIF2). eIF2 phosphorylation results in cap-dependent protein synthesis shutoff, relieving the burden of the accumulation of proteins in the ER and evidenced as a reduction in total cellular protein expression (30).

Reassortants carrying the SBVp32 M segments reached higher virus titers in the brains of infected mice and were more infectious in vitro. We hypothesize that during serial virus passage and without pressure from neutralizing antibodies, the Gc protein accumulated mutations that allow more efficient entry and, thus, faster spread. However, it remains to be determined if this virus could be viable or if it could be more pathogenic in its natural hosts given the possibility that it could be better neutralized. It is possible that faster entry or higher-level replication conferred by the SBVp32 Gc glycoprotein allows earlier expression of other viral proteins (such as the viral polymerase and/or NSm), leading to faster induction of cellular protein shutoff than in the wild-type virus. Unfortunately, we have not been able to express the viral glycoproteins to high levels using a transient-transfection system to test the role of Gc in protein shutoff independently of other viral components. These data could be an indication that expression of Gc leads to protein synthesis shutoff resulting in the repression of its own plasmid.

We showed that single point mutations in Gc (positions 1894, 2236, and 2411) rescue the inability of the S segment of SBVp32 to induce total cellular protein shutoff. There are currently <10 SBV M segment sequences derived from field isolates; thus, our understanding of the true genetic diversity of this virus and the consensus sequence circulating in affected countries is very limited. Interestingly, SBVp32 mutation at position 2236 exists in the field,

### Table 2: Organs in which the presence of SBV mRNA was evaluated by in situ hybridization

| Organ                  | Presence of mRNA<sup>a</sup> |
|------------------------|-------------------------------|
|                        | SBV Mouse 1 | Mouse 2 | SBVp32 Mouse 3 | Mouse 4 | Controls Mouse 5 | Mouse 6 |
| Salivary gland         | 0           | 0       | +              | 0       | 0                 | 0       |
| Mandibular lymph node  | +           | 0       | +++            | +++     | 0                 | ND      |
| Pharynx                | 0           | 0       | ND             | 0       | 0                 | 0       |
| Thyroid gland          | 0           | ND      | 0              | ND      | 0                 | 0       |
| Lungs                  | 0           | 0       | 0              | 0       | 0                 | 0       |
| Thymus                 | 0           | ND      | ND             | ND      | ND                | ND      |
| Heart                  | 0           | 0       | 0              | +++     | 0                 | 0       |
| Liver                  | ++++        | 0       | ++++           | +++     | 0                 | 0       |
| Spleen                 | ++++        | 0       | ++++           | ++++    | 0                 | 0       |
| Kidney                 | 0           | 0       | +++            | 0       | 0                 | 0       |
| Testis                 | 0           | 0       | 0              | 0       | 0                 | 0       |
| Cerebellum             | 0           | 0       | 0              | 0       | 0                 | 0       |
| Brain stem             | 0           | 0       | 0              | 0       | 0                 | 0       |
| Cerebrum               | 0           | 0       | 0              | 0       | 0                 | 0       |
| Stomach                | 0           | 0       | 0              | 0       | 0                 | 0       |
| Small intestine        | 0           | 0       | +              | +       | 0                 | 0       |
| Large intestine        | 0           | 0       | 0              | +++     | 0                 | 0       |
| Pancreas               | 0           | 0       | 0              | 0       | 0                 | 0       |
| Mesenteric lymph node  | ++          | ND      | ++++           | ND      | 0                 | 0       |
| Spinal cord            | 0           | 0       | 0              | 0       | 0                 | 0       |
| Bone marrow            | ++++        | +       | ++++           | ++++    | 0                 | 0       |

<sup>a</sup> Mice 1 to 6 are individual animals. 0, no positive cells; +, single positive cells; +++, small number of positive cells; ++++, small to moderate number of positive cells; +++++, moderate number of positive cells; ++++++, moderate to large number of positive cells; +++++++, large number of positive cells; ND, not determined.
indicating that it can lead to viable virus. Given that we found a consistent positive correlation between the ability of our reassortants to induce protein shutoff and the ability of the reassortants to be more pathogenic in our mouse model of infection, we can conclude that a single amino acid change in the Gc glycoprotein can potentially rescue attenuated phenotypes based on mutations of the S segment. Importantly, we also showed that the defect in inducing host protein shutoff by an NSs-NSm double-deletion mutant can be rescued by amino acid changes in the Gc glycoprotein and that at least one of the changes exists in viruses circulating in the field. Therefore, live attenuated vaccines based on deletions of NSs and NSm require further careful consideration.

FUNDING INFORMATION
This work was funded by the Medical Research Council (MRC) and the Wellcome Trust. Funding was also provided by the Italian Ministry of Health (grant IZS A&M MSRCT06.11), the Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony, Germany, the Zoonotic Anticipation and Preparedness Initiative (Innovative Medicines Initiative grant 115760), and the Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (scholarship number 15/05778-5).

REFERENCES
1. Hoffmann B, Scheuch M, Geiger I, Gerhauser I, Weigand M, Hahn K, Herder V, Wohlsein P, Habierski A, Mouchantat E, Randall RE, Adamson CS. 2012. Novel orthobunyavirus in cattle, Europe, 2011. Emerg Infect Dis 18:469–472. http://dx.doi.org/10.3201/eid1803.111905.
2. Jack C, Anstaeott O, Adams J, Noad R, Brownlie J, Mertens P. 2012. Evidence of seroconversion to SBV in camels. Vet Rec 170:603. http://dx.doi.org/10.1136/vr.e3939.
3. Wensman LD, Kristensen B, Kirkeby C, Rasmussen J, Bodker R, Botner A. 2005. Caliciviruses as vectors of Schmallenberg virus. Emerg Infect Dis 11:3209–3216. http://dx.doi.org/10.3201/eid1107.040939.
4. Elbers AR, Meuwissen R, van Weezep E, Kooi EA, van der Poel WH. 2013. Schmallenberg virus in Culicoides biting midges in the Netherlands in 2012. Transbound Emerg Dis 60:339–342. http://dx.doi.org/10.1111/tbed.12128.
5. Urogi H, Inaba Y, Goto Y, Miura Y, Takahashi H. 1975. Serologic evidence for etiologic role of Akabane virus in epizootic arthropod-specific hemorrhagic meningoencephalitis in cattle in Japan, 1972–1974. Arch Virol 47:71–83. http://dx.doi.org/10.1007/BF01315594.
6. Calisher CH. 1996. History, classification, and taxonomy of viruses in the family Bunyaviridae, p 1–17. In Elliott RM (ed), The Bunyaviridae. Plenum Press, New York, NY.
7. Gerhauser I, Weigand M, Hahn K, Herder V, Wohlsein P, Habierski A, Varela M, Palmarini M, Baumgartner W. 2014. Lack of Schmallenberg virus in ruminant brain tissues archived from 1961 to 2010 in Germany. J Comp Pathol 150:151–154. http://dx.doi.org/10.1016/j.jcpa.2013.11.210.
8. Mouchantat S, Wernike K, Lutz W, Hoffmann B, Ulrich RG, Borner K, Wittstadt U, Beer M. 2015. A broad spectrum screening of Schmallenberg virus antibodies in wildlife animals in Germany. Vet Res 46:69. http://dx.doi.org/10.1186/s13567-015-0232-x.
9. Varela M, Schnettler E, Caporale M, Murchia C, Barry G, McFarlane M, McGregor E, Piras IM, Shaw A, Lamm C, Janowicz A, Beer M, Glass M, Herder V, Hahn K, Baumgartner W, Kohl A, Palmarini M. 2013. Schmallenberg virus pathogenesis, tropism and interaction with the innate immune system of the host. PLoS Pathog 9:e1003133. http://dx.doi.org/10.1371/journal.ppat.1003133.
10. Barry G, Varela M, Ratinier M, Blomstrom AL, Caporale M, Seehusen F, Hahn K, Schnettler E, Baumgartner W, Kohl A, Palmarini M. 2014. NSs protein of Schmallenberg virus counteracts the antiviral response of the cell by inhibiting its transcriptional machinery. J Gen Virol 95:1640–1646. http://dx.doi.org/10.1099/vir.0.065425-0.
11. Elliot RM, Blakpor G, van Kuippenberg IC, Koudriakov E, Li P, McLees A, Shi X, Szemiel AM. 2013. Establishment of a reverse genetics system for Schmallenberg virus, a newly emerged orthobunyavirus in Europe. J Gen Virol 94:851–859. http://dx.doi.org/10.1099/vir.0.049981-0.
12. BMJ Group. 2013. VMD authorises SBV vaccine for use in the UK. Vet Rec 172:543.
13. Kraatz F, Wernike K, Hechinger S, Konig P, Granzow H, Reimann I, Beer M. 2015. Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge. J Virol 89:1825–1837. http://dx.doi.org/10.1128/JVI.02729-14.
14. Arnaud F, Black SG, Murphy L, Griffiths DJ, Neil SJ, Spencer TE, Palmarini M. 2010. Interplay between ovine bone marrow stromal cell antigen 2/etherin and endogenous retroviruses. J Virol 84:4413–4425. http://dx.doi.org/10.1128/JVI.00299-10.
15. Varela M, Chow YH, Sturkie C, Murcia P, Palmarini M. 2006. Association of RON tyrosine kinase with the Jaagsiekte sheep retrovirus envelope glycoprotein. Virology 350:347–357. http://dx.doi.org/10.1016/j.virol.2006.01.040.
16. Liu KP, Arnaud F, Palmarini M. 2007. The transdominant endogenous retrovirus enJS56A1 associates with and blocks intracellular trafficking of Jaagsiekte sheep retrovirus Gag. J Virol 81:1762–1772. http://dx.doi.org/10.1128/JVI.01859-06.
17. Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, Armezzani A, Bayoumy A, Rixon F, Shaw A, Palmarini M. 2011. Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS Pathog 7:e1002477. http://dx.doi.org/10.1371/journal.ppat.1002477.
18. Hahn K, Habierski A, Herder V, Wohlsein P, Peters M, Hansmann F, Baumgartner W. 2013. Schmallenberg virus in central nervous system of ruminants. Emerg Infect Dis 19:154–155. http://dx.doi.org/10.3201/eid1901.120764.
19. Elliott RM. 2014. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol 12:673–685. http://dx.doi.org/10.1038/nrmicro3332.
20. Lennete EH, Koprowski H. 1944. Influence of age on the susceptibility of mice to infection with certain neurotropic viruses. J Immunol 49:175–191.
21. Oliver KR, Scallan MF, Dyson H, Fazakerley JK. 1997. Susceptibility to a neurotropic virus and its changing distribution in the developing brain is a function of CNS maturity. J Neurovirol 3:39–48. http://dx.doi.org/10.1080/13550287909511486.
22. Mohamed M, McLees A, Elliott RM. 2009. Viruses in the Anopheles A, Anopheles B, and Tette serogroups in the Orthobunyavirus genus (family Bunyaviridae) do not encode an NSs protein. J Virol 83:7612–7618. http://dx.doi.org/10.1128/JVI.02080-08.
23. Patterson JL, Holloway B, Kolakofsky D. 1984. Lasse Crouse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. J Virol 52:215–222.
24. Shi X, Kohl A, Leonard VH, Li P, McLees A, Elliott RM. 2006. Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. J Virol 80:8089–8099. http://dx.doi.org/10.1128/JVI.00579-06.
25. Shi X, Kohl A, Li P, Elliott RM. 2007. Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis. J Virol 81:10151–10160. http://dx.doi.org/10.1128/JVI.00573-07.
26. Hellen CU, Sarnow P. 2001. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 15:1593–1612. http://dx.doi.org/10.1101/gad.891101.
27. Hanson PJ, Zhang HM, Hemida MG, Ye X, Qiu Y, Yang D. 2012. IRES-dependent translational control during virus-induced endoplasmic reticulum stress and apoptosis. Front Microbiol 3:92. http://dx.doi.org/10.3389/fmicb.2012.00092.
28. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497.